BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Total Assets
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) holds total assets worth Rs3.22 Billion INR (≈ $34.87 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BALAXI net asset value for net asset value and shareholders' equity analysis.
BALAXI PHARMACEUTICALS LIMITED - Total Assets Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's total assets have evolved over time, based on quarterly financial data.
BALAXI PHARMACEUTICALS LIMITED - Asset Composition Analysis
Current Asset Composition (March 2025)
BALAXI PHARMACEUTICALS LIMITED's total assets of Rs3.22 Billion consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 12.7% |
| Accounts Receivable | Rs1.11 Billion | 35.7% |
| Inventory | Rs784.81 Million | 25.3% |
| Property, Plant & Equipment | Rs363.11 Million | 11.7% |
| Intangible Assets | Rs6.61 Million | 0.2% |
| Goodwill | Rs267.45 Million | 8.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BALAXI market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BALAXI PHARMACEUTICALS LIMITED's current assets represent 78.2% of total assets in 2025, an increase from 62.1% in 2013.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2025, down from 42.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 35.7% of total assets.
BALAXI PHARMACEUTICALS LIMITED Competitors by Total Assets
Key competitors of BALAXI PHARMACEUTICALS LIMITED based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
BALAXI PHARMACEUTICALS LIMITED - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.96 | 3.45 | 2.33 |
| Quick Ratio | 2.66 | 2.22 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.78 Billion | Rs1.70 Billion | Rs413.15 Million |
BALAXI PHARMACEUTICALS LIMITED - Advanced Valuation Insights
This section examines the relationship between BALAXI PHARMACEUTICALS LIMITED's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 20.1% |
| Total Assets | Rs3.10 Billion |
| Market Capitalization | $15.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values BALAXI PHARMACEUTICALS LIMITED's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BALAXI PHARMACEUTICALS LIMITED's assets grew by 20.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual total assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.10 Billion ≈ $33.56 Million |
+20.13% |
| 2024-03-31 | Rs2.58 Billion ≈ $27.94 Million |
+7.79% |
| 2023-03-31 | Rs2.40 Billion ≈ $25.92 Million |
+35.81% |
| 2022-03-31 | Rs1.76 Billion ≈ $19.08 Million |
+77.04% |
| 2021-03-31 | Rs996.80 Million ≈ $10.78 Million |
+177.11% |
| 2020-03-31 | Rs359.71 Million ≈ $3.89 Million |
+488.93% |
| 2019-03-31 | Rs61.08 Million ≈ $660.54K |
+262.13% |
| 2018-03-31 | Rs16.87 Million ≈ $182.41K |
-34.54% |
| 2017-03-31 | Rs25.77 Million ≈ $278.65K |
+7117.47% |
| 2016-03-31 | Rs356.99K ≈ $3.86K |
-3.02% |
| 2015-03-31 | Rs368.10K ≈ $3.98K |
-96.94% |
| 2014-03-31 | Rs12.04 Million ≈ $130.21K |
-2.76% |
| 2013-03-31 | Rs12.38 Million ≈ $133.91K |
-- |
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more